Commercial Partnership in the Agri-bio Market
16 January 2015
Avacta Group plc
("Avacta" or "the Group")
Commercial Partnership Targeting the Agri-bio Reagents Market
Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare announces that it has entered into a commercial agreement with Agrisera AB, a Sweden based, global provider of antibodies to the protein sciences market, to develop Affimer based purification systems for proteomics applications.
Agrisera has been established for over thirty years and specialises in development and marketing of antibodies and related research tools globally, offering several thousand antibodies for plant and algal cell biology research. They are joint market leaders in the plant antibodies market with Merck-Millipore with a 27% share each.
Plant proteomics is a rapidly growing field like human proteomics in which scientists are working to understand the relationships between proteins and diseases to drive a revolution in the way issues such as food security, safety and human health are addressed. In proteomics, samples are often dominated by highly abundant proteins making it difficult to detect the rare proteins that may be the most important in a disease process. Therefore, frequently, samples need to be enriched for non-abundant proteins to facilitate proteomic analysis. This is currently done using antibodies to extract the highly abundant proteins using a bead based affinity column.
Affimers are an engineered alternative to antibodies. They have advantages over antibodies in this depletion application because of their small size, leading to higher packing density and therefore greater capacity of the depletion system, lower manufacturing cost, greater stability and robustness.
The market opportunity, whilst difficult to quantitate accurately, is significant. Avacta Life Sciences and Agrisera have entered into an agreement to develop Affimer based depletion products with improved performance and economics compared to the current systems. The agreement provides for commercialisation to be carried out by Agrisera under an undisclosed revenue sharing model.
Dr Alastair Smith, Avacta Group Chief Executive Officer, commented:
"Agrisera are a well respected, high quality provider of research tools for plant sciences research and I am delighted that we will be working with them to develop the first Affimer based product for the agri-bio market.
"This market, in general, is not as well served as the human life sciences market by the large antibody suppliers, so there is a great opportunity for Avacta to establish Affimers in a growing market where there are many gaps, as well as pushing forward with our plans to address the human life sciences market."
Greger Nordlund, Chief Executive Officer of Agrisera, said:
"We are very pleased to enter into this collaboration with Avacta employing their promising Affimer technology. This collaboration is fully in line with Agrisera's strategy to develop and provide novel, effective tools and reagents to the research community."
Enquiries:
|
Avacta Group plc Alastair Smith, Chief Executive Officer Tim Sykes, Chief Financial Officer |
Tel: +44 (0) 844 414 0452 |
|
|
|
|
Numis Securities Limited Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking |
Tel: +44 (0) 207 260 1000 |
|
|
|
|
Media Enquiries Walbrook PR Ltd Mike Wort / Anna Dunphy |
Tel: +44 (0) 207 933 8780 avacta@walbrookpr.com |
About Avacta Group plc - www.avacta.com
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:
|
Avacta Analytical
|
High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development. |
|
Avacta Animal Health
|
Veterinary diagnostics reference laboratory and diagnostic kit provider. |
|
Avacta Life Sciences
|
Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development. |
This information is provided by RNS
Latest directors dealings
- 43 minutes ago Diageo
- 49 minutes ago IMI
- 1 hour ago Softcat
- 4 hours ago Tertiary Minerals
- 4 hours ago Hargreaves Services